Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Head of troubled CDC anthrax lab has resigned
23 Jul 2014 at 11:34am
NEW YORK (AP) ? The head of the government lab that potentially exposed workers to live anthrax has resigned, an agency spokesman said Wednesday.
Judges in health care rulings vote party line
23 Jul 2014 at 12:20am
WASHINGTON (AP) ? In rapid succession, six federal judges on two appeals courts weighed in on a key component of President Barack Obama's health care law. Their votes lined up precisely with the party of the president who appointed them.
Ohio woman has long road ahead after rock attack
22 Jul 2014 at 12:42pm
DANVILLE, Pa. (AP) ? Doctors had a simple goal when they first saw how a football-size rock thrown from an interstate overpass in Pennsylvania had shattered Sharon Budd's skull ? to keep her alive.
Paracetamol no better than placebo for low back pain, study finds
23 Jul 2014 at 3:58pm
By Kate Kelland LONDON (Reuters) - Paracetamol, a painkiller universally recommended to treat people with acute low back pain, does not speed recovery or reduce pain from the condition, according to the results of a large trial published on Thursday. A study published in The Lancet medical journal found that the popular pain medicine was no better than placebo, or dummy pills, for hastening recovery from acute bouts of low back pain or easing pain levels, function, sleep or quality of life. Researchers said the findings challenge the universal endorsement of paracetamol as the first choice painkiller for lower back pain. "We need to reconsider the universal recommendation to provide paracetamol as a first-line treatment," said Christopher Williams, who led the study at the University of Sydney in Australia.
Not Enough Time for Intimacy?
23 Jul 2014 at 3:39pm
Diary of a Depressed Night Owl: The Search for Happiness Late Into the Evening
23 Jul 2014 at 3:25pm
Abuse of U.S. generic-drug rules costs billions -report
23 Jul 2014 at 3:04pm
By Diane Bartz WASHINGTON (Reuters) - U.S. rules that ensure prescription medicines are not misused have been manipulated by brand-name drug companies to fight off generic competitors, costing consumers billions of dollars, according to a report released on Wednesday. Called "risk evaluation and mitigation strategies" (REMS), these U.S. Food and Drug Administration rules are meant to secure the safe distribution of dangerous medicines. This has delayed the arrival of 40 potential generic drugs, costing consumers some $5.4 billion a year, according to the report by Matrix Global Advisors and released by the generic drug trade group.
Over 10 million U.S. adults gain coverage under Obamacare: study
23 Jul 2014 at 3:00pm
An estimated 10.3 million American adults have gained health coverage since Obamacare enrollment began last October, with the biggest gains among young adults and Hispanics, according to a study published on Wednesday. The findings by researchers from the Harvard School of Public Health, Brigham and Women's Hospital in Boston and the federal government are based on data pointing to a 5.2 percentage point drop in the U.S. uninsured rate since last September for Americans aged 18-64. The study, which appeared in the New England Journal of Medicine, also found evidence that more Americans had a personal doctor and fewer difficulties paying for medical care within the first six months of gaining insurance. The law known as Obamacare, President Barack Obama's signature domestic policy achievement, provides federally subsidized private coverage through new online insurance marketplaces and an expansion of Medicaid in 26 states and Washington, D.C. The U.S. Department of Health and Human Services said in May that more than 8 million Americans signed up for private plans through new online insurance marketplaces during a six-month open enrollment period.
A Simple Prescription for Lower Health Care Costs
23 Jul 2014 at 2:53pm
Journal raises concern about blood-thinning drug
23 Jul 2014 at 2:20pm
A key selling point of the drug known as Dabigatran or Pradaxa was that it required no blood-level monitoring, as does competitor warfarin. Dabigatran's maker, Boehringer Ingelheim, had said the drug was better than warfarin at reducing stroke in people with irregular heart rhythm, with a similar risk of major bleeds, according to the British Medical Journal (BMJ). Based on its own probe, the journal accused Boehringer of concealing information that blood-level monitoring could in fact reduce major bleeds by up to 30-40 percent compared to warfarin. According to BMJ investigations editor Deborah Cohen, who conducted the research, millions of people take the anti-clotting drug, with blood levels found to vary greatly between patients.
Checking pulse could help detect risk of a second stroke
23 Jul 2014 at 2:20pm
By Kathryn Doyle NEW YORK (Reuters Health) - Stroke patients and their families can be taught to monitor the patient?s pulse and detect irregular heartbeats that might lead to another stroke, according to a new study. Of people who have a stroke, 40% will suffer another one within the next 10 years, said lead author Dr. Bernd Kallmunzer of the Department of Neurology at Universitatsklinikum Erlangen in Germany. Taking a pulse reading can detect atrial fibrillation, a major risk factor for stroke, and facilitate appropriate treatment to reduce the risk of another stroke or death, Kallmunzer told Reuters Health by email. The study team tested how accurately patients and their families could detect fibrillation just by taking a pulse.
Robot bladder surgery fails to deliver fewer complications
23 Jul 2014 at 2:16pm
By Gene Emery NEW YORK (Reuters Health) - Using robotic techniques to remove a cancerous bladder doesn't reduce the risk of complications compared with conventional "open" surgery, according to a new comparison of 118 patients conducted by surgeons at the Memorial Sloan Kettering Cancer Center in New York. The study, detailed in the New England Journal of Medicine, marks the first ongoing comparison of the risks and benefits of the two techniques. Past studies concluded that the robotic technique meant less time in the hospital and fewer complications but they were done by looking back at the records of already-treated patients. "There's been a lot of hype surrounding robots and it's been hard to gain perspective," said Dr. Vincent Laudone, one of the coauthors.
Hispanic Americans need tailored heart care: report
23 Jul 2014 at 1:36pm
By Andrew M. Seaman NEW YORK (Reuters Health) - Hispanic Americans make up the fastest growing minority group in the U.S. and healthcare professionals need to better understand their unique heart health risks in order to tailor their care, according to a new report from the American Heart Association. ?We hope that we can move into a new era when we can look at this population with a more nuanced perspective,? said Dr. Carlos Rodriguez, the report?s lead author and a cardiologist at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina. Cardiovascular disease includes conditions that affect the heart and blood vessels, such as heart failure, strokes and high blood pressure. The size and growth of the U.S. Hispanic community makes the group?s health vital to the nation and to reaching the American Heart Association?s 2020 goals, Rodriguez and his co-authors write in the journal Circulation.
Exclusive: CDC says lab director behind anthrax mishap resigns
23 Jul 2014 at 1:24pm
By David Morgan WASHINGTON (Reuters) - The director of a U.S. government bioterror lab that potentially exposed scores of workers to live anthrax last month has resigned, the U.S. Centers for Disease Control and Prevention said on Wednesday. Michael Farrell, head of the CDC's Bioterror Rapid Response and Advanced Technology Laboratory (BRRAT) in Atlanta, had been reassigned from his position last month after the agency disclosed the safety breaches. He submitted his resignation on Tuesday, the CDC said. ?I can confirm that he was the team lead for the BRRAT lab since 2009 and that he?s resigned from that position,? said CDC spokesman Thomas Skinner.
Panel's report likely to tie farm antibiotics to human resistance
23 Jul 2014 at 1:18pm
By P.J. Huffstutter CHICAGO (Reuters) - A White House advisory committee is expected to acknowledge the link between antimicrobial resistance in humans and livestock being fed antibiotics when it issues its report in the next few weeks, according to the transcript of a committee meeting held earlier this month. In the transcript, council co-Chairman Eric Lander said there was "clear documentation" that antibiotic-resistant microbes can transfer from farm animals to humans. "That judicious use [of antibiotics] in agriculture right now is absolutely essential," Lander said in the transcript. "There may come a point where one will say it's justified to say no use." Governments and public health officials worldwide have begun ramping up efforts to fight so-called "super bugs" - microbes that have mutated to be resistant to medically important antibiotics such as cephalosporins, which are used to treat hospital-acquired infections like blood infections and meningitis.